A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors

ModraPac001 (MP1) and ModraPac005 (MP5) are novel oral paclitaxel formulations that are coadministered with the cytochrome P450 3A4 inhibitor ritonavir (r), enabling daily low‐dose metronomic (LDM) treatment. The primary aim of this study was to determine the safety, pharmacokinetics and maximum tol...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical pharmacology in drug development 2021-06, Vol.10 (6), p.607-621
Main Authors:	Weger, Vincent A., Vermunt, Marit A.C., Stuurman, Frederik E., Burylo, Artur M., Damoiseaux, David, Hendrikx, Jeroen J.M.A., Sawicki, Emilia, Moes, Johannes J., Huitema, Alwin D.R., Nuijen, Bastiaan, Rosing, Hilde, Mergui‐Roelvink, Marja, Beijnen, Jos H., Marchetti, Serena
Format:	Article
Language:	English
Subjects:	Administration, Oral Aged antiangiogenic treatment Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antiretroviral drugs Antiviral drugs Area Under Curve Cancer therapies Dose-Response Relationship, Drug Drug Administration Schedule Drug therapy Female Humans low‐dose metronomic therapy Male Maximum Tolerated Dose Middle Aged Neoplasms - drug therapy oral paclitaxel Paclitaxel - administration & dosage Pharmacology ritonavir Ritonavir - administration & dosage solid tumors Terminology Tumors
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!